Challenges and future perspectives in the clinical translation of PLGA nanoparticles for PD The previously discussed preclinical studies have shown the benefits of loading drugs and natural compounds into PLGA nanoparticles to enhance therapeutic efficacy, minimize systemic toxicity, and overcome peripheral side effects associated with PD medications
A physician can help determine what problem is actually being treated
Abdulmughni LA, Al-Sanabani JA, Gilan WM, Issa MA, Jowah HM
Muscle loss accelerates, metabolic rate drops faster, and long-term maintenance becomes harder
Biodegradable scaffolds: Polyethylene glycol (PEG)peptidepoly (lactic-co-glycolic acid) (PLGA) copolymers, where enzymatic cleavage disrupts the amphiphilic structure and triggers payload release ( Biocompatibility: Peptide linkers are naturally metabolized, reducing long-term accumulation risk (37)